PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Chemotherapeutic Activity of Dietary Supplementation of Silymarin Combined with Capecitabine and Irinotecan in 1,2 Dimethylhydrazine-Induced Mouse Colon Carcinogenesis
Version 1
: Received: 29 January 2024 / Approved: 29 January 2024 / Online: 29 January 2024 (13:33:56 CET)
How to cite:
Hassani, S.; Malekinejad, H.; Khadem-Ansari, M. H.; Abbasi, A.; Kheradmand, F. Chemotherapeutic Activity of Dietary Supplementation of Silymarin Combined with Capecitabine and Irinotecan in 1,2 Dimethylhydrazine-Induced Mouse Colon Carcinogenesis. Preprints2024, 2024012037. https://doi.org/10.20944/preprints202401.2037.v1
Hassani, S.; Malekinejad, H.; Khadem-Ansari, M. H.; Abbasi, A.; Kheradmand, F. Chemotherapeutic Activity of Dietary Supplementation of Silymarin Combined with Capecitabine and Irinotecan in 1,2 Dimethylhydrazine-Induced Mouse Colon Carcinogenesis. Preprints 2024, 2024012037. https://doi.org/10.20944/preprints202401.2037.v1
Hassani, S.; Malekinejad, H.; Khadem-Ansari, M. H.; Abbasi, A.; Kheradmand, F. Chemotherapeutic Activity of Dietary Supplementation of Silymarin Combined with Capecitabine and Irinotecan in 1,2 Dimethylhydrazine-Induced Mouse Colon Carcinogenesis. Preprints2024, 2024012037. https://doi.org/10.20944/preprints202401.2037.v1
APA Style
Hassani, S., Malekinejad, H., Khadem-Ansari, M. H., Abbasi, A., & Kheradmand, F. (2024). Chemotherapeutic Activity of Dietary Supplementation of Silymarin Combined with Capecitabine and Irinotecan in 1,2 Dimethylhydrazine-Induced Mouse Colon Carcinogenesis. Preprints. https://doi.org/10.20944/preprints202401.2037.v1
Chicago/Turabian Style
Hassani, S., Ata Abbasi and Fatemeh Kheradmand. 2024 "Chemotherapeutic Activity of Dietary Supplementation of Silymarin Combined with Capecitabine and Irinotecan in 1,2 Dimethylhydrazine-Induced Mouse Colon Carcinogenesis" Preprints. https://doi.org/10.20944/preprints202401.2037.v1
Abstract
The flavonoid silymarin (SMN) has been widely used in preclinical and clinical studies to treat various types of cancer, either alone or in combination with chemotherapy agents. Herein, we investigated the therapeutic efficacy of SMN and its combination with capecitabine (CAP) and irinotecan (IRI) in a mouse model of colon cancer. A modified diet supplemented with SMN (2500 ppm) with mono- and combined therapy of CAP and IRI were used following 1, 2 dimethylhydrazine (DMH)-induced colon cancer. The lipid profile, liver function tests, and cytokine levels were measured. Additionally, the lipid peroxidation and inflammation indices as well as the antioxidant activities were examined. Eventually, western blotting analysis for colonic BAX and Bcl-2 levels and histopathological examination of colon sections were carried out. SMN alone and in combination with the chemotherapeutic agents could attenuate the DMH-induced hyperlipidemia and elevated liver function enzyme levels. SMN supplementation with chemotherapy agents could also improve antioxidant activity and reverse the elevated levels of lipid peroxidation and inflammatory markers. Furthermore, significant upregulation of BAX and downregulation of Bcl-2 were observed. Besides, carcinogen-induced polyp multiplicity, dysplastic, and inflammatory changes were ameliorated considerably by treatment regimens. Our results showed that the potential anticancer properties of SMN could enhance the therapeutic effects of chemotherapy agents and reduce hepatotoxicity.
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
